Traversing the genomic landscape of prostate cancer from diagnosis to death

Article metrics

The clinical spectrum of prostate cancer ranges from curable, local disease to widely metastatic, lethal cancer. Two new prostate cancer genome studies provide the first glimpse at both ends of this spectrum.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Genome-wide alterations in primary and metastatic prostate cancer.

References

  1. 1

    Barbieri, C.E et al. Nat. Genet. 44, 685–689 (2012).

  2. 2

    Grasso, C.S. et al. Nature published online, doi:10.1038/nature11125 (20 May 2012).

  3. 3

    Berger, M.F. et al. Nature 470, 214–220 (2011).

  4. 4

    Robbins, C.M. et al. Genome Res. 21, 47–55 (2011).

  5. 5

    Taylor, B.S. et al. Cancer Cell 18, 11–22 (2010).

  6. 6

    Demichelis, F. et al. Genes Chromosom. Cancer 48, 366–380 (2009).

  7. 7

    Cuzick, J. et al. Lancet Oncol. 12, 245–255 (2011).

  8. 8

    Tomlins, S.A. et al. Nature 448, 595–599 (2007).

  9. 9

    Shen, M.M. & Abate-Shen, C. Genes Dev. 24, 1967–2000 (2010).

  10. 10

    Palanisamy, N. et al. Nat. Med. 16, 793–798 (2010).

  11. 11

    Tomlins, S.A. et al. Cancer Cell 13, 519–528 (2008).

  12. 12

    Furukawa, M., He, Y.J., Borchers, C. & Xiong, Y. Nat. Cell Biol. 5, 1001–1007 (2003).

  13. 13

    Cuzick, J. et al. Br. J. Cancer 106, 1095–1099 (2012).

Download references

Author information

Correspondence to Charles L Sawyers.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hieronymus, H., Sawyers, C. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet 44, 613–614 (2012) doi:10.1038/ng.2301

Download citation

Further reading